Log out Go to App
Go to App

Learning Materials

Features

Discover

Chapter 40: Problem 20

In the Kahn head to head trial which of the following therapies was not evaluated? a. Avonex b. Betaseron c. Copaxone d. Rebif

Short Answer

Expert verified
Answer: Both b. Betaseron and c. Copaxone were not evaluated in the Kahn Head to Head trial.

Step by step solution

01

Understand the Kahn Head to Head trial

The Kahn Head to Head trial, also known as EVIDENCE trial, was a comparative study of the efficacy and safety of two multiple sclerosis (MS) therapies, Avonex (interferon beta-1a) and Rebif (interferon beta-1a), in patients with relapsing-remitting multiple sclerosis.
02

Identify the evaluated therapies

From our understanding of the Kahn Head to Head trial, we know that the study compared two therapies, Avonex and Rebif.
03

Eliminate the evaluated therapies from the options

Given that the trial compared Avonex and Rebif, we can eliminate these two options (a and d) from our consideration as they were evaluated in the trial.
04

Identify the therapy that was not evaluated

Now we are left with two options: b. Betaseron c. Copaxone Since we know that the trial compared only two therapies (Avonex and Rebif), and they do not include Betaseron nor Copaxone, we can conclude that neither of these therapies was evaluated in the Kahn Head to Head trial. So, the correct answer is both b. Betaseron and c. Copaxone.

Unlock Step-by-Step Solutions & Ace Your Exams!

  • Full Textbook Solutions

    Get detailed explanations and key concepts

  • Unlimited Al creation

    Al flashcards, explanations, exams and more...

  • Ads-free access

    To over 500 millions flashcards

  • Money-back guarantee

    We refund you if you fail your exam.

Start your free trial

Over 30 million students worldwide already upgrade their learning with Vaia!

One App. One Place for Learning.

All the tools & learning materials you need for study success - in one app.

Get started for free

Most popular questions from this chapter

What clinical information, in association with verification of the clinical symptoms of optic neuritis and fatigue would be sufficient to verify that the diagnosis is definitive MS using the revised MacDonald criteria?

The FDA approved therapy for relapsing remitting MS with the smallest \(\%\) reduction in relapses at 12 months by the Johnson Class I data a. Avonex b. Betaseron c. Copaxone d. Rebif

Score for an individual with normal motor function on the Kurtzke Expanded Disability Scoring Scale (EDSS) a. 0 b. 1 c. 5 d. 10

Brain atrophy is considered significant is it exceeds the these normal changes related to aging a. \(<0.5-1 \%\) b. \(>0.5-1 \%\) c. \(>1-1.5 \%\) d. \(>5 \%\)

Your brother continues to progress rapidly with no apparent remission even on standard immunotherapy for RR-MS. What therapy is FDA approved for rapidly progressing MS?
See all solutions

Recommended explanations on Biology Textbooks

Chemistry of Life

Read Explanation

Genetic Information

Read Explanation

Biological Molecules

Read Explanation

Cell Communication

Read Explanation

Communicable Diseases

Read Explanation

Ecology

Read Explanation
View all explanations

What do you think about this solution?

We value your feedback to improve our textbook solutions.

Study anywhere. Anytime. Across all devices.

Sign-up for free